Abstracts Archive - Page 1481 of 2425 - ACR Meeting Abstracts

Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 950 • 2016 ACR/ARHP Annual Meeting
Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Gabriele Simonini¹, Erika Scoccimarro¹, Irene Pontikaki², Giovanna Ferrara³, Teresa Giani¹, Andrea Taddio³, Pier Luigi Meroni⁴ and Rolando Cimaz¹, ¹Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Rheumatology Department, Gaetano Pini Institute, University of Milan, Milano, Italy, ³Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", University of Trieste, Trieste, Italy, ⁴Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy
Background/Purpose: Information regarding the history of patients with JIA after systemic treatment withdrawal would be helpful in driving the choice of duration therapy. While some…
Abstract Number: 951 • 2016 ACR/ARHP Annual Meeting
A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry
Bente Glintborg¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Niels Steen Krogh³, Anne Gitte Loft⁴, Jakob Espesen², Jimmi Olsen², Oliver Hendricks⁵, Jolanta Grydehøj², Inger Marie Jensen Hansen², Michael Veedfald Sørensen², Stavros Chrysidis², Birgitte Lange Andersen², Natalia Manilo², Mette Klarlund², Lis Smedegaard Andersen², Henrik Nordin², Salome Kristensen², Jesper Nørregaard² and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark
Background/Purpose: According to national guidelines issued in May 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish…
Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Michael Weinblatt¹, Clifton Bingham III², Gerd-Rüdiger Burmester³, Vivian P. Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Ronald van Vollenhoven⁸, Brenda VanLunen⁹, Cécile Ecoffet¹⁰, Christopher Cioffi⁹ and Paul Emery¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
Abstract Number: 953 • 2016 ACR/ARHP Annual Meeting
Comparison of 10-Years Disease Outcomes of Rheumatoid Arthritis Patients with Continued Low Disease Activity on Methotrexate with or without Initial Combination Therapy with Infliximab or Prednisone and Sulfasalazine
SA Bergstra¹, RBM Landewé^2,3, TWJ Huizinga¹ and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Low disease activity and remission in rheumatoid arthritis (RA) patients is achieved earlier and in higher frequency when the initial treatment includes a combination…
Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Frank Behrens¹, Tanja Rossmanith², Michaela Koehm³, Rieke Alten⁴, Martin Aringer⁵, GR Burmester⁶, Eugen Feist⁷, Klaus Krüger⁸, Ulf Müller-Ladner⁹, Andrea Rubbert-Roth¹⁰, Siegfried Wassenberg¹¹, Hans-Peter Tony¹², Herbert Kellner¹³, Marina Backhaus¹⁴ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ⁴Schlosspark-Klinik University Medicine, Berlin, Germany, ⁵Abteilung für Rheumatologie, Dresden, Germany, ⁶Charité – University Medicine Berlin, Berlin, Germany, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Praxiszentrum St. Bonifatius, München, Germany, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰Division Rheuamatology, University Köln, Köln, Germany, ¹¹Rheumazentrum, Ratingen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Rheumatology Patient Care, Munchen, Germany, ¹⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…
Abstract Number: 955 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion
Hiroshi Uda and Osamu Saiki, Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: A period of 4 weeks (w) has been recommended as the interval between tocilizumab (TCZ) infusions. The cost of TCZ is very high, which…
Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
SA Bergstra¹, OM Olivas Vergara¹, G Akdemir¹, GM Steup-Beekman², HK Ronday³, JB Harbers⁴, RBM Landewé^5,6 and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands, The Hague, Netherlands, ³Department of Rheumatology, HAGA hospital, The Hague, Netherlands, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, Roosendaal, Netherlands, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…
Abstract Number: 957 • 2016 ACR/ARHP Annual Meeting
International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials
Ana-Maria Orbai¹, Maarten de Wit², Philip J Mease³, Judy A. Shea⁴, Laure Gossec⁵, Ying Ying Leung⁶, William Tillett⁷, Musaab Elmamoun⁸, Kristina Callis Duffin⁹, Willemina Campbell¹⁰, Robin Christensen¹¹, Laura C. Coates¹², Emma Dures¹³, Lihi Eder¹⁴, Oliver FitzGerald¹⁵, Dafna D. Gladman¹⁶, Niti Goel¹⁷, Suzanne Grieb¹⁸, Sarah Hewlett¹⁹, Pil Hoejgaard²⁰, Umut Kalyoncu^21,22, Christine Lindsay²³, Neil J. McHugh²⁴, Bev Shea²⁵, Ingrid Steinkoenig²⁶, Vibeke Strand²⁷ and Alexis Ogdie²⁸, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology, Paris 06 University, Paris, France, ⁶North District Hospital, Hong Kong, China, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁹Department of Dermatology, University of Utah, Salt Lake City, UT, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹²University of Leeds, Leeds, United Kingdom, ¹³Academic Rheumatology, Bristol, University of the West of England, Bristol, Bristol, United Kingdom, ¹⁴Women's College Research Institute, University of Toronto, Toronto, ON, Canada, ¹⁵Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ¹⁶Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁷Quintiles; Duke University School of Medicine, Durham, NC, ¹⁸Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ¹⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ²⁰The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark, ²¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²³Medical Affairs, Amgen Inc, Thousand Oaks, CA, ²⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, ²⁵University of Ottawa, Ottawa, ON, Canada, ²⁶Patient Research Partner,, Cleveland, OH, ²⁷School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) was developed by Group for Research and Assessment…
Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Philip J Mease¹, Mark C. Genovese², Michael Weinblatt³, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Heikki T. Mansikka⁴, Amit Khatri⁴, Ahmed A. Othman⁴, Neil Wishart⁴, John Liu⁴ and Robert J. Padley⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Stanford University Medical Center, Palo Alto, CA, ³Brigham and Women’s Hospital, Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…
Abstract Number: 959 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Philip J Mease¹, Masato Okada², Mitsumasa Kishimoto², Catherine L. Shuler³, Hilde Carlier³, Chen-Yen Lin³, Jiani Mou³, Susan R Moriarty³, Chin H. Lee³ and Dafna D Gladman⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is an IgG4 monoclonal antibody that binds with high affinity and specificity to the proinflammatory cytokine IL-17A. In this phase 3 study…
Abstract Number: 960 • 2016 ACR/ARHP Annual Meeting
Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Laura Savage¹, Mark Goodfield², Elizabeth M.A. Hensor³, Paul Emery³ and Dennis McGonagle⁴, ¹NIHR Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Leeds Centre for Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Subclinical enthesopathy is recognised in up to 50% of psoriasis patients and is thought to precede inflammatory PsA. It is not known if effective…
Abstract Number: 961 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
Philip J Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens^7,8, Pellet Pascale⁹, Evie Maria Delicha¹⁰, Luminita Pricop¹¹ and Shephard Mpofu¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²UC San Diego School of Medicine, La Jolla, CA, ³Dallas VA Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁶Monash University, Melbourne, Australia, ⁷University of Hasselt, Hasselt, Belgium, ⁸Maastricht University Hospital, Maastricht, Netherlands, ⁹Novartis Pharma AG, basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 963 • 2016 ACR/ARHP Annual Meeting
Treatment of Homocysteine Improves Urine Protein/Cr Ratio in SLE
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Homocysteine is a proven prospective risk factor for stroke and arterial thrombosis in SLE. However, checking for homocysteine and treating high levels is actually…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].